{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-009966","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2025-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.239414+00:00","generated_at":"2026-05-17T10:26:35.473890+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CEL-SCI files Breakthrough Medicine Designation with Saudi FDA for Multikine; signs MOU with Dallah Pharma","bullets":["Breakthrough Medicine Designation application filed with SFDA by Dallah Pharma for Multikine.","MOU signed with Dallah Pharma for commercialization; final partnership expected Q3 2025.","SFDA response time ~60 days; if granted, Multikine available for patient access and reimbursement in Saudi Arabia.","Dallah Healthcare serves over 3 million patients annually via network of hospitals and clinics."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-009966","json":"https://secwatch.observer/filing/0001654954-25-009966.json","markdown":"https://secwatch.observer/filing/0001654954-25-009966.md","text":"https://secwatch.observer/filing/0001654954-25-009966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495425009966/0001654954-25-009966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495425009966/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:26:35.473890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}